Key facts
- This page summarizes Raymond Joseph Tesi's Form 4 filing for Inmune Bio, Inc. (INMB).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Sep 2024, 20:48.
Raymond Joseph Tesi - 12 Sep 2024 Form 4 Insider Report for Inmune Bio, Inc. (INMB)
- Reporting relationship
- President and CEO, Director, 10%+ Owner
- Issuer ticker
- INMB
- Reported as of
- 12 Sep 2024
- Net transaction value
- +$99,970
- SEC form
- 4
- Accepted by SEC
- 16 Sep 2024, 20:48:44 UTC
- Prior SEC filing
- 12 Jun 2024
- Next SEC filing
- 09 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tesi Raymond Joseph
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Raymond Joseph Tesi filed Form 4 for Inmune Bio, Inc. (INMB) on 16 Sep 2024.
Change
- Previous filing in this sequence was filed on 12 Jun 2024.
- Current net transaction value: +$99,970.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INMB
transaction
Common Stock
Purchase
- Transaction value
- $98,048
- Shares
- +15,380
- Change %
- +1%
- Price
- $6.38
- Shares after
- 1,554,106
- Date
- 12 Sep 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INMB
transaction
Derivative
Common Stock Warrants (right to buy)
Purchase
- Transaction value
- $1,922
- Shares
- +15,380
- Change %
- Price
- $0.1250*
- Shares after
- 15,380
- Date
- 12 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,380
- Exercise price
- $6.40
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $6.50, for an aggregate purchase price of $13,000,000 pursuant to a securities purchase agreement dated September 12, 2024. The Warrants are exercisable on or after March 16, 2025 and will terminate on March 16, 2030 unless such termination is accelerated pursuant to the terms of the Warrants (the "Termination Date"), provided, however, in the event that the Warrant is held by Insiders and the Termination Date is during a period that such Insiders are subject to a blackout with respect to trading in the Company's common stock, such Insiders will have an additional 60 days from the termination of the blackout to exercise the Warrant. The exercise price the Warrants is $6.40 per share subject to adjustment as provided in the Warrant.